Today: 9 June 2026
Browse Category

NYSE:CLX 4 November 2025 - 6 June 2026

Clorox Stock Slumps After Profit Forecast Cut as Purell Deal and Oil Costs Bite

Clorox slips as CEO departure announced

Clorox shares fell 6.4% to $90.02 Friday after CEO Linda Rendle said she would step down for health reasons, intensifying concerns over weak sales and profit outlook. Trading volume jumped to 4.6 million shares. The stock underperformed peers as the S&P 500 and Dow rose. Rendle will remain in her roles until a successor is named.
30 May 2026
·
Clorox Stock Sinks After Outlook Cut: Why the Bleach Maker’s Profit Squeeze Isn’t Over

Clorox Stock Sinks After Outlook Cut: Why the Bleach Maker’s Profit Squeeze Isn’t Over

Clorox lowered its fiscal 2026 adjusted earnings forecast to $5.45–$5.65 per share, down from $5.95–$6.30, citing higher costs and slower recovery in some categories. Shares dropped 9.7% to $87.11 Friday. Net sales for the third quarter were $1.67 billion, nearly flat year-over-year. The GOJO acquisition is expected to dilute adjusted earnings by 2 to 4 cents per share.
2 May 2026
·
Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next

Procter & Gamble stock rises as Wall Street turns defensive — what traders watch next

Procter & Gamble shares rose 1.1% to $151.58 Friday afternoon as investors moved into consumer-staples stocks amid inflation concerns and policy uncertainty. The S&P 500 fell 0.4% while the XLP staples ETF gained 1.2%. Senate obstacles raised the risk of a partial U.S. government shutdown before the midnight funding deadline. Investors await the Feb. 6 jobs report and further policy signals.
30 January 2026
····
Clorox stock (CLX) ends week higher: what to watch on dividend, Glad shift, ERP fallout

Clorox stock (CLX) ends week higher: what to watch on dividend, Glad shift, ERP fallout

Clorox shares closed up 1.9% at $106.19 Friday, outperforming Procter & Gamble and Colgate-Palmolive, but remain 35% below their 52-week high. Clorox will buy Procter & Gamble’s 20% stake in the Glad joint venture at its Jan. 31 termination. The company expects ERP-related disruptions to cut fiscal 2026 earnings by about 90 cents per share. Clorox shares trade ex-dividend Jan. 28.
11 January 2026
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir’s ‘Otherworldly’ Earnings & Wegovy Deal Buzz Spark After-Hours Stock Fireworks

Palantir shares rose after Q3 results beat estimates and the company raised its outlook for a third straight quarter, citing surging AI platform demand. Hims & Hers stock jumped 7% post-market as it entered talks to offer Novo Nordisk’s Wegovy, despite mixed earnings. Sarepta plunged over 20% after a key Duchenne drug trial failed its main goal. Sanmina soared 18% on a strong earnings beat and guidance far above Wall Street forecasts.
4 November 2025
·······

Stock Market Today

  • Wheat Futures Rise as Export Inspections Show Mixed Data
    June 9, 2026, 9:19 AM EDT. Wheat futures gained on Monday, with Chicago SRW up 5-7 cents, KC HRW up 9-11 cents, and MPLS spring wheat rising slightly. Export inspections reported 319,730 MT shipped in the week ending June 4, down 20.65% from the previous week and 1.38% below last year. Mexico led exports with 83,211 MT. Managed money increased net shorts in Chicago wheat futures to 57,871 contracts, hitting a record bear move since 2006. Ukraine's wheat crop estimate rose 1.8 MMT to 21.7 MMT. July 26 CBOT Wheat futures closed at $5.86 ½, up 6 ½ cents, reflecting bullish momentum amid volatile trading conditions.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Go toTop